Recent advancements in immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting the programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) axis, such as nivolumab and pembrolizumab, have revolutionized the treatment landscape for advanced ESCC. Here, CD274 is linked to esophageal squamous cell carcinoma.